Summary
Bimagrumab is a monoclonal antibody targeting type II activin receptors. In a randomized trial, bimagrumab combined with semaglutide led to up to 17.8kg weight reduction, surpassing the effects of semaglutide alone (up to 14.2kg). Notably, the combination p
Source: Nature.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
